Due to the characteristics of Mexico, the world pharmaceutical industry is interested in the country, but more facilities of health authorities are required to attract investments linked to the Mexico Plan, said Roberto Martínez Olivera, General Director of Bepharma.
All countries are interested in Mexico for their geographical situation, the population of practically 140 million is an attraction for any pharmaceutical company
said the sector specialist also in an interview with The day.
– What is needed as part of what President Claudia Sheinbaum announces in the Mexico Plan?
–Facilitate the procedures of the health authority.
Martínez Olivera commented that The only way that a country has to develop a self -sufficiency strategy is not only to manufacture them, but to give the facilities for international experts and companies to establish themselves in Mexico
.
He mentioned that The impulse to research will help. Instead of developing clinical research in other countries to come to Mexico to establish their research centers. It is very aligned because it is that countries and companies look at Mexico as an investment destination and that will bring us a self -sufficiency
.
He commented that in the Bepharma event, which will be held on March 31 and April 1, which will be attended by medicines and health supplies, as well as distributors from more than 160 countries, the purpose is to establish commercial relations. It is about making a commercial link by which companies can penetrate other markets and also look for new suppliers and new medications
.
He added that the Mexican territory has a privileged place to establish commercial ties with all of America. That has also helped us to generate new commercial exchange and benefits us in that there are more medications, be innovative, greater competition because sometimes for a drug there is only one manufacturer
.
Due to the closeness with the United States, imports depend 80 percent, while exports reach 60 percent, so greater diversification is necessary.
He stressed that the Mexican pharmaceutical industry, the second most important in Latin America, after that of Brazil, has plants, maquila, with innovation, new international products and certifications that has the capacity to supply a local market to export.
We must look out, both to export and grow our gross domestic product and to bring new therapeutic solutions to Mexican patients.
He pointed out that the market grew 9 percent in 2024, so it is estimated that for this year it advances between 6 and 9 points, mainly due to greater demand for the population.